Worldwide Healthcare (WWH) slightly underperformed in the first half of its financial year as gains from its list of possible bid targets and gains by Eli Lilly and biotech company Natera were partly offset by falls in Boston Scientific and AstraZeneca. The £1.3bn investment trust saw net asset value including dividends grow 9.3%, behind the 9.9% of its MSCI World Health Care index. However, shareholders enjoyed a 14.8% total return as the share price discount narrowed from 10% to 5.5% in response to £115.9m of buybacks, of which there have been been £30m more since the half-year-end. Activist hedge fund Saba Capital disclosed a 5.4% position in May last year.
David Batchelor, senior analyst at QuotedData, said: “WWH’s strong absolute return is encouraging and suggests that investor appetite for healthcare stocks is recovering, although the trust’s failure to outperform its benchmark is disappointing given its highly active approach. Particularly striking is the reversal in fortunes during the period, with significant outperformance in the first three months more than wiped out in the following three. This illustrates both the opportunities and risks associated with WWH’s substantial overweight to emerging biotechnology companies, where sentiment can change rapidly. The managers’ decision to reduce biotechnology and medical technology exposure while increasing allocations to pharmaceuticals and diagnostics looks sensible, although the portfolio remains positioned to benefit from a sustained recovery in appetite for innovative healthcare businesses. The departure of longstanding lead manager Sven Borho is a significant change, but Trevor Polischuk’s experience and the continuity of the investment process should provide reassurance.
“The narrowing discount is welcome, but the scale of intervention required to achieve it remains concerning. WWH spent £115.9m on buybacks during the half year, equivalent to more than 8% of its opening shares in issue, and has continued buying back shares since. While these purchases enhance NAV for remaining shareholders, such a substantial and prolonged programme raises questions about the sustainability of the current approach. Ultimately, stronger and more consistent relative performance will be needed to rebuild demand for the shares and reduce the reliance on buybacks.”
Saba Capital has lifted its position in Gore Street Energy Storage Fund (GSF) to 22.3% of voting rights, comprising 11.9% held in shares and 10.4% through a total return swap. This is up from 21.7%. The UK-listed battery energy storage investment trust survived a wind-up vote brought by Saba in September and signed a two-year Texas tolling agreement in October. Shares in the £244m investment trust stand on a 34% discount to net asset value.
Gresham House Energy Storage (GRID) has declared a dividend of 0.25p per share fulfilling its prior commitment to a single dividend of at least 0.25p in 2026 while the battery fund prioritises reinvestment in its assets to deliver a three-year growth plan and progresses a sale process.